Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Knowing what to look for and how to manage the changes can make a difference. Secondary progressive MS (SPMS) can affect both physical health and cognitive abilities. Results from a small 2025 ...

Enrollment is now complete in two Phase 3 clinical trials testing vidofludimus calcium in adults with relapsing forms of ...

MS is marked by chronic inflammation and demyelination in the central nervous system. Demyelination is the process in which ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Location : Boston Convention & Exhibition Center, Boston, MA ...

Here’s what to know about remission and secondary progressive MS. Most people with MS initially receive a diagnosis of relapsing-remitting MS (RRMS). In this type of MS, periods of disease ...

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click ...

A new study reveals that mitochondrial dysfunction plays a central role in the loss of Purkinje neurons in the cerebellum, ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...